Gerold Meinhardt
Vice President, Asset & Portfolio Management & Global Team Lead, Enhertu Daiichi Sankyo
Seminars
Tuesday 4th November 2025
Spotlighting Enhertu’s Historic HER2-Positive Solid Tumor Agnostic & Metastatic Breast Cancer HER2-Ultralow Approvals
8:30 am
- Breaking down readouts from DESTINY clinical trials which led to tumor-agnostic HER2-positive solid tumor approval
- Outlining DB06 data and results of Enhertu in HER2 ultralow patient populations: what impact does target expression have across tumor types
- Evaluating the impact of Enhertu demonstrating superiority vs. chemotherapy in metastatic breast cancer to advance ADCs towards earlier-line oncology treatments
